



ASX ANNOUNCEMENT

6 January 2015

## ***Completion of Exercise of Underwritten Cynata Listed 31 December 2014 Options***

**Melbourne, Australia; 6 January 2015:** Stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that **over 97%** of the Company's listed December 2014 options (ASX: CYPO) were exercised by holders of those options in advance of the 31 December 2014 expiration date. Pursuant to the option underwriting agreement announced in November 2014 the underwriters will now be required to take up the shortfall of 393,987 options.

The exercise of CYPO Options has provided Cynata with gross proceeds of approximately \$2.9 million.

"This high proportion of Option exercise is an outstanding result for Cynata and demonstrates real support by the Company's security holders", said Executive Chairman, Dr Stewart Washer. "We enter the New Year of 2015 with good cash reserves and a growing global interest in stem cell therapies. Our Cymerus™ stem cell manufacturing platform has been well developed over the past year as the scalable manufacturing solution for mesenchymal stem cells. I see 2015 as the year of partnerships for Cynata."

**Media contacts:** Dr Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email [stewart.washer@cynata.com](mailto:stewart.washer@cynata.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.